Biogen (NASDAQ: BIIB) reported Q2 EPS of $3.60, $0.43 better than the analyst estimate of $3.17. Revenue for the quarter came in at $2.74 billion versus the consensus estimate of $2.43 billion.

GUIDANCE:

Biogen sees FY2026 EPS of $12.00-$13.00, versus the consensus of $12.72.

For earnings history and earnings-related data on Biogen (BIIB) click here.